

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number  
WO 03/057220 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/4453,  
31/5355, 31/4166, 31/423, 31/44, C07D 233/70, 233/78,  
413/04, 401/04, 491/08

Science Park South, Third Avenue, Harlow, Essex CM19  
5AW (GB).

(21) International Application Number: PCT/GB03/00020

(74) Agent: KONDO, Rie; GlaxoSmithKline, CN925.1, 980  
Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 7 January 2003 (07.01.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0200283.0 8 January 2002 (08.01.2002) GB

(71) Applicant (*for all designated States except US*): GLAXO  
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BROMIDGE,  
Steven, Mark [GB/GB]; GlaxoSmithKline, New Frontiers  
Science Park South, Third Avenue, Harlow, Essex CM19  
5AW (GB). LOVELL, Peter, John [GB/GB]; Glaxo-  
SmithKline, New Frontiers Science Park South, Third  
Avenue, Harlow, Essex CM19 5AW (GB). GOODACRE,  
Caroline [GB/GB]; GlaxoSmithKline, New Frontiers


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: CYCLIC UREA DERIVATIVES WITH 5-HT<sub>2C</sub> RECEPTOR ACTIVITY



(57) Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT<sub>2C</sub> receptor activity, are disclosed: wherein a is 0, 1, 2, 3, 4 or 5; b is 1, 2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, -CONH-, -NHCO- or together with R<sup>2</sup> form a benzoxazolone group; R<sup>1</sup> is halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylthio, hydroxy, amino, mono- or di-C<sub>1-6</sub>alkylamino, nitro, CN, CF<sub>3</sub>, OCF<sub>3</sub>, aryl, arylC<sub>1-6</sub>alkyl, arylC<sub>1-6</sub>alkyloxy or arylC<sub>1-6</sub>alkylthio; R<sup>2</sup> is hydrogen, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, haloC<sub>1-6</sub>alkyl or haloC<sub>1-6</sub>alkoxy; R<sup>3</sup> is: (i) -NR<sup>4</sup>R<sup>5</sup> where R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or arylC<sub>1-6</sub>alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ===== is a single bond or a double bond; and X is CH<sub>2</sub> or C=O (when ===== is a single bond) or X is CH (when ===== is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.